72 results about "Immune gene" patented technology

The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.

Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.

A process for preparing the antigen protein used for hog cholera vaccine includes extracting hog cholera virus RNA, reverse transcription to obtain the immune gene E2 of hog cholera virus, using E2 as template for PCR while inserting them to expression carrier of Bichia yeast, introducing the recombinant expression carrier to Bichia yeast, screening the recombinant Bichia yeast, discriminating its expression product testing its immunoactivity, determining the chosen recombinant yeast, testing and analyzing its culture condition, choosing the optimal culture condition, culturing the recombinant yeast and preparing the antigen protein of said vaccine.

The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.

The invention discloses a kit for detecting a capripoxvirus serum antibody based on a synthetic peptide. A preparation method of the kit comprises the following steps of 1, designing a short-peptide aiming at a capripoxvirus main immunogene P32, 2, synthesizing a peptide fragment by a conventional peptide synthesis technology, 3, preparing the kit for detecting a capripoxvirus serum antibody based on a synthetic peptide, and 4, optimizing conditions and finishing the preparation of the kit for detecting a capripoxvirus serum antibody. A coating antigen adopted by the kit is an external synthetic immunoactive peptide fragment, reduces the danger of totvirus use and prevents virus diffusion and escape. The synthetic peptide adopted by the kit has high purity, has immunological characteristics similar to capripoxvirus particles, and can replace capripoxvirus particles and be used as an antigen for detection and thus the kit realizes sensitive, specific, safe and reliable detection of a capripoxvirus serum antibody.

The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera Ileibacterium and Dubosiella, including their species I. valens (I. valens) and Dubosiella newyorkensis (D. newy), respectively, and closely related OTUs within the family Erysipelotrichaceae that resemble either Ileibacterium spp. or Dubosiella spp. with 90% 16S rRNA sequence identity, for modulating weight and intestinal inflammation and immunity (including modulating intestinal immune gene expression such as, e.g., modulating expression of RORγT, IL-17A, IL-17F, RegIIIγ, Relmβ, and Defβ), as well as for treatment and diagnosis of (i) obesity and related conditions such as metabolic syndrome and diabetes mellitus; (ii) allergic and autoimmune diseases, and (iii) gastrointestinal disorders (such as, e.g., inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and celiac disease).

Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-β inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.

The invention discloses a method for efficiently and rapidly evaluating the prognosis of a patient with stage II colorectal cancer based on an immune gene expression characteristic spectrum and a construction method of an IRGCRC II prognosis model; the IRGCRC II prognosis model is adopted to evaluate the prognosis of the patient with stage II colorectal cancer, and the IRGCRC II prognosis model comprises CCL28, FGF18, IL23A, LIF, SLIT2 and VGF immune genes. According to the IRGCRC II prognosis model constructed by the invention, a gene model tool for evaluating the prognosis of the II-stage CRC patient is constructed on the basis of the content determination of six immune genes in the body of the II-stage colorectal cancer patient with high expression, and a new evaluation system is provided for evaluating the survival outcome of the II-stage colorectal cancer patient; and a new basis is provided for selection of treatment schemes such as whether the patient is subjected to chemical treatment or not.

The invention discloses an immune repertoire biological information analysis process based on molecular markers. In the process, single-chain immune globulin genes with the same sequence are selected,and primers and UMI sequences with the same structure are added to 3' ends or 5' ends of the selected single-chain immune globulin genes; after addition is completed, PCR amplification is performed on the immune genes to obtain a test sequence, and the test sequence is filtered; after filtering, the UMI sequence carried by the immune genes is corrected by establishing a directed acyclic tree, then the immune genes marked by the corrected UMI sequence are corrected, and the corrected immune genes are assembled; and finally the assembled immune genes are subjected to statistical analysis and reporting. According to the process, through correction of UMI and correction of the immune genes, the influences of amplification errors and sequencing errors on immune gene sequencing are effectivelyremoved, and the accuracy of sequencing data is improved.

The invention aims at the medical biotechnology, relates to a high-throughput sequencing method based on a primer barcode technology and an application thereof in study of immune genomics, and specifically relates to a T-cell high-throughput sequencing method based on a marking method of cDNA molecules. Specifically, the method comprises the following steps of extracting RNA from a sample, performing reverse transcription on the RNA to obtain cDNA, designing a specific primer according to the obtained cDNA, constituting a random primer barcode by a downstream primer of the designed specific primer, a random barcode and a sequencing joint in a series manner, adding excessive obtained random primer barcode in the obtained cDNA molecules, carrying out high-throughput sequencing by using the sequencing joint in the random primer barcode, carrying out VDJ comparison on sequencing data; analyzing a CDR3 sequence and establishing immune library spectra. The method reduces deflection and error generated in a PCR amplification process. The number of the cDNA molecules can be quantized according to the specific primer barcode corresponding to a given cDNA sequence.

A super-antigen immune gene treater for liver cancer is characterized by that the liver cancer cell specific regulation sequence mediated super-antigen moleculae and co-stimulation moleculae are target expressed in liver cancer cells to specifically enhance the immunogenicity of cancer cell and the recognition action to immunoeffect cells. after the treater is injected to cancer region, it can effectively kill cancer cells.

The present invention provides a method for predicting prognosis of hepatocellular carcinoma patients based on measurement of the relative level of expression of a combination of 15 immune genes of interest, or a subset thereof, in the tumors of such patients. Tumor material can come from surgical resection or biopsy. The relative gene expression information may be combined in an algorithm. The signature can be used by itself or in combination with other information such as stage information.

The invention discloses an application of a scoring system based on an immunogene pair in prediction of immunotherapy curative effect and prognosis of a non-small cell lung cancer patient. The scoring system disclosed by the invention is carried out based on the following four immune related gene pairs: CCL2 and VEGFA genes, CDK1 and CXCL9 genes, HLA-DOB and LCK genes, and IL-12A and TBX21 genes. The IRGP index (IRGPI) calculated based on an immune gene pair scoring system constructed by the invention is significantly related to the progression-free lifetime of a non-small cell lung cancer patient receiving anti-PD-1 immunotherapy. Therefore, the four immune-related gene pairs and the scoring system constructed according to the four immune-related gene pairs can be used for performing curative effect and prognosis prediction on the non-small cell lung cancer patient receiving anti-PD-1 immunotherapy.

The invention provides an O-type foot and mouth disease virus strain with improved replication titer as well as a construction method and application thereof, and belongs to the technical field of biological products. Through a reverse genetic manipulation technology of the foot and mouth disease virus, a G-H ring gene of the foot and mouth disease virus O / NXYCh / CHA / 2018 strain is further used for replacing a corresponding gene on a recombinant virus skeleton of a main immune gene of the chimeric foot and mouth disease virus O / XJ / CHA / 2017 strain, the time of causing 100% infected cell lesion by the constructed recombinant virus rHN / XJ / NXGH is remarkably shortened to 12 h, and the time of causing 100% infected cell lesion by the recombinant virus rHN / XJ / NXGH is remarkably shortened to 12 h. And the replication titer of infected cells for 12 hours is improved by more than 5 times. The recombinant virus is continuous in passage and good in hereditary stability, and replacement of the G-H ring does not affect immunogenicity of the vaccine. Therefore, the recombinant foot-and-mouth disease virus strain rHN / XJ / NXGH provided by the invention has the potential to be used as a vaccine candidate strain for effectively preventing and controlling the O-type foot-and-mouth disease in China.

The invention discloses application of a group of immune-related molecular markers in tissues identified based on a TCGA database in esophageal cancer prognosis. The application specifically comprises the following steps: establishing an immune gene prognosis model related to esophageal cancer prognosis; the method for establishing the model comprises the following steps: step 1, collecting and processing data; step 2, screening differentially expressed genes; and step 3, identifying differentially expressed immune related genes; step 4, performing transcription factor analysis and construction of a transcription factor immune differential expression gene regulation and control network; step 5, performing survival analysis; and step 6, establishing a prognosis risk index evaluation model based on esophageal cancer immune related genes.

The invention provides a dilapidated wall three-in-one type royal jelly product. The product has the following main characteristics: the product comprises tablets, paste products and soft capsules. The product is characterized in that taking preparation of 10 kg dilapidated wall three-in-one type royal jelly product tablets as an example, the tablets comprise the following components by weight: 6.35-6.37 kg of royal jelly freeze-dried powder, 2.72-2.74 kg of queen bee placenta powder, 0.49-0.51 kg of selenium-enriched yeast powder, 0.25-0.27 kg of ingredient maltodextrin, 0.10-0.13 kg of microcrystalline cellulose, and 0.03-0.04 kg film-coating liquid coating premixing agent. The rest paste products and the capsules have the same components and technique with the tablets, but specific numerical values are different. The product has the advantages that the royal jelly, the selenium element and the queen bee placenta are integrated, the cellular immunity gene activating theory is combined, and all nutrition ingredients are superfinely dilapidated walls to enter human bodies in a form of micromolecules so as to accord with the human body circulating rules.

The invention discloses a microRNA (micro ribonucleic acid) related to soybean phytophthora resistance and belongs to the field of molecular biology of soybeans. 223 phytophthora-resistant genes and 256 miRNAs are obtained by means of screening known relevant disease-resistant immune genes. A phytophthora-resistance-related miRNA-Target predicting system is established by means of expression profile sequencing, rigorous bioinformatics analysis and real-time quantitative PCR (polymerase chain reaction) detection and can predict functions of the miRNAs, so that screening and identifying efficiency for soybean phytophthora resisting genes and the miRNAs is improved greatly. A MIRNA-target relation classification method is provided, that a Plant-pathogen interaction path plays a key role in phytophthora resisting is discovered, and that a gma-miR482c-3p serves as a main ingredient of the Plant-pathogen interaction path and is closely related to the soybean phytophthora resistance is verified.

The invention relates to an epinephelus coioides interferon IFNgamma1 gene, a protein coded by the gene and an application of the protein in preparing a novel immunopotentiator. According to the invention, an opened reading frame of the IFNgamma1 gene is cloned from head-kidney RNAs (Ribonucleic Acid) of epinephelus coioides through a method of screening a genome database and designing specific primer amplification. The nucleotide sequence of the gene is shown as SEQIDNO:2. The amino acid sequence of the protein coded is shown as SEQIDNO:1. Through initial verification, the epinephelus coioides interferon IFNgamma1 protein can induce associated expression of immunogenes and can be developed to natural immunopotentiators or immunologic adjuvants for fishes.

The present invention relates to a non-PCR (polymerase chain reaction) process, particularly a transcription-based amplification method, for amplifying and cloning sequences containing a variable domain sequence such as an immunoglobulin variable domain sequence from the immunological gene repertoire. The present invention comtemplates the expression of antibody library in either in an in vivo expression vector or in an in vitro transcription / translation system. Isolation of a gene coding for a receptor having the ability to bind a preselected ligand and receptors produced by the gene isolated by the method is also contemplated.

An immune gene expression signature is associated with clinical features in tumor samples and can be used to predict the immunological state of a tumor and / or sensitivity of the tumor to immune therapy.

The invention relates to the field of data mining in bioinformatics, in particular to a multi-source data fusion framework for revealing a breast cancer immune escape regulation mechanism. The framework is implemented mainly according to the following steps of: (1) collecting related data of breast cancer samples and normal samples; (2) clustering the breast cancer samples by using NMF (Non-negative Matrix Factorization) to obtain sample subgroup types; (3) comparing the breast cancer samples with the normal samples obtained from GTEx, and finding out differentially expressed related genes; (4) designing a regulation and control analysis algorithm based on ATAC-SEQ data to find immune related genes; (5) verifying the relationship between the TF and the immune gene by using five general databases; and (6) analyzing whether the immune gene obtained according to the framework affects the survival of the patient. The invention provides a multi-source data fusion framework for revealing a breast cancer immune escape regulation mechanism, and the framework has important significance for researching drug relocation and realizing precise medical treatment. The biological significance of the research process and the research result can be effectively improved. More importantly, the single-sample law analysis method can be used for deeply exploring the heterogeneity of a tumor, and has important significance on precise medical practice.

An immune gene expression signature is associated with clinical features in tumor samples and can be used to predict the immunological state of a tumor and / or sensitivity of the tumor to immune therapy.

An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and / or chemosensitivity.

The invention discloses a mixed attribute feature large data set clustering algorithm based on a CSA. The algorithm comprises the following steps: S1, an antibody community is initialized; S2, clone operation is carried out; S3, immunization gene operation is carried out; S4, clone selection operation is carried out; S5, clone death operation is carried out; S6, single-step operator iteration is carried out; and S7, antibody encoding is carried out, and steps from the second to the sixth are repeated until a clustering archetype is converged to an optimal solution. The clonal selection algorithm (CSA) is used for large data set clustering analysis. The clustering performance is evaluated in the large data set, and an experiment result shows that the method can effectively find out the clustering structure in the data. When clustering analysis is carried out on a large amount of data with numerical values and generic mixed features, the algorithm based on the CSA is quick in convergence speed and does not depend on selection of the initial archetype, and convergence to the global optimal solution with the possibility of 1 can be realized.

The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.

The invention discloses application of recombinant vibrio parahaemolyticus flagellin in improvement of fish immunity. It is found that the recombinant vibrio parahaemolyticus flagellin can induce expression of related immune genes and participate in activation of corresponding immune signal channels, the immunity of fishes is remarkably improved, the recombinant vibrio parahaemolyticus flagellin is expected to be developed into a natural fish immunopotentiator or immunologic adjuvant, and then fish diseases caused by vibrio parahaemolyticus are prevented or treated. Therefore, the recombinantvibrio parahaemolyticus flagellin has a good application prospect in improving fish immunity and preparing a fish immunopotentiator or immunologic adjuvant.

The invention relates to a N protein gene of duck-origin coronavirus ZZ2004, and a clone method and application thereof. The N protein gene sequence has the overall length of 1230 bp, and codes N proteins of 409 amino acid residues. The virus sequence with higher homology is found through random PCR, a pair of specific primers is designed by using the sequence as the template and the corresponding fragments are amplified, and then the fragments are respectively connected with a pMD18-T carrier to clone the N protein gene of the virus. Due to that the N gene is an important immune gene and has important effect in the aspects of cellular immunity, humoral immunity and local immunity. The research of the N gene of the invention favors the discovery of the IBV heteromorphosis regularity, the distinguishing of the different serotypes and the further development of novel genetic engineering vaccine, and plays important role in the effective prevention of the IBV.

The invention discloses recombinant rabies viruses BNSP-CDV-F and BNSP-CDV-H in which canine distemper virus main immune genes are embedded. The recombinant viruses take a rabies virus strain SAD-B19as a framework, CDV-F and CDV-H genes shown in SEQ ID NO.1 and SEQ ID NO.2 are separately inserted between an N gene and P gene of a recombinant plasmid SAD-19 full-length cDNA, and finally recombinant rabies virus strains BNSP-CDV-F and BNSP-CDV-H are saved through a reverse genetic operation technology. The recombinant viruses BNSP-CDV-F and BNSP-CDV-H can express fusion protein and hemagglutinin protein of canine distemper viruses; after a vaccine prepared by mixing the recombinant viruses is used for immunizing animals, a great number of anti-rabies virus antibodies and main immune gene antibodies resistant to the canine distemper viruses can be induced and generated. The cost of the vaccine can also be reduced, and the recombinant viruses BNSP-CDV-F and BNSP-CDV-H have a good application and popularization prospect.

Disclosed is a complex immuno-gene medical composition activating NK cells to enhance host immune system. The composition is usage of a combination of a plurality of cytokines, combined usage of the kinds of Th1 and Th2 cytokines. Th2 cytokine antagonizes TGF-β inhibiting NK cells to disable the inhibition of immune system, and Th1 cytokine activates NK cells in host to enhance the ability fighting against tumor cells. By means of the complex immuno-gene medical composition, removal of tumor cells is expectable.

The invention concerns a tbid gene, protein coding by tbid gene and uses of said gene and protein in tumor drug preparation. In the invention, single chain antibody e23sFv gene which can idiocraticly identify and bind HER-2 positive tumor cell is used to construct a tbid gene with PEA transmembrane structural domain and active truncated bid gene (tbid)which has strong specificity,high activity ,low immunogenicity,sustainable execution on tumor. The invention constructs secretion type immunological target gene. after gene is expressed and secreted, its can produce effector molecule to kill tumor cell. The gene therapy strategy possessing simultaneously the cell immunity and humoral immunity character has obvious advantages compared with other strategy. Immunological tbid gene the invention constructed is safe, highly effective and continuous effect. The invention is hoped to provide a novel method for HER-2 tumor target therapy.